Defending citizens and servicemembers against chemical or biological attack, as well as the threat of emerging diseases, is a priority mission for the National Institutes of Health (NIH), part of the U.S. Department of Health and Human Services and the Fort Detrick campus. NIH is the nation’s medical research agency. It spearheads the charge against diseases such as Ebola, cancer and tick-borne illness by working with leaders across a spectrum of scientific disciplines to improve health and save lives. Their Counter Act Program identifies and funds scientists developing select drugs and treatments, including projects managed by Mesa Science Associates Inc. (MSA).
MSA is a veteran owned company based at the Frederick Innovative Technology Center, Inc. (FITCI) on Metropolitan Ct. The company provides consulting services and program management to drug developers and investigators from industry, government and academia. This year Mr. Michael Mesa, MSA President, and his team are attending the 2018 annual meeting of drug developers and investigators as both delegates and sponsors. The gathering is funded through the NIH Counter Act program and is hosted by the University of Colorado in the Denver on June 13 and 14. Mesa and MSA host the poster session reception on Wednesday, 6/13, and have a booth at the meeting, highlighting recent achievements and collaborative opportunities.
Dr. Ken Dretchen, MSA CSO, is Co-Investigator on two U-O1 grants held by a Principal Investigator from the University of California San Diego. The MSA team provides technical and scientific support to the holder of both grants. Dr. Dretchen is also listed as Co-Investigator on a U-01 grant application submitted by a Counter Act investigator from the University of Colorado and is a member of the PhRMA Foundation Basic Pharmacology Advisory Committee.
Kathie Callahan Brady, CEO of FITCI, says MSA is emerging as a national industry contender. “As a science and technology incubator, we are privileged to be so close to Fort Detrick and the cutting-edge therapies advanced by NIH. Mesa Science Associates is a perfect complement. In just a few short years since its inception, the company is making an impact on a national scale. It’s good business and good for the region, but that collective effort reaches even further as each project serves to protect and improve countless lives.”
Mr. Mesa says the team is looking forward to re-joining colleagues, past and present, while learning about the progress on Counter Act funded projects. For more information about Mesa Science Associates please visit http://www.mesascience.com.
